Aroa Biosurgery Ltd 주요 수익원은 Soft Tissue Repair Products이며, 최신 수익 발표에서 수익은 76,443,631입니다. 지역별로는 United States이 Aroa Biosurgery Ltd의 주요 시장이며, 수익은 73,903,915입니다.
Aroa Biosurgery Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 Aroa Biosurgery Ltd의 순손실은 $0입니다.
Aroa Biosurgery Ltd에 부채가 있나요?
no, Aroa Biosurgery Ltd의 부채는 0입니다.
Aroa Biosurgery Ltd의 발행 주식은 몇 주인가요?
Aroa Biosurgery Ltd의 총 발행 주식은 0주입니다.
주요 통계
이전 종가
$0.52
시가
$0.5
일일 범위
$0.5 - $0.52
52주 범위
$0.35 - $0.522
거래량
35.0K
평균 거래량
90
배당수익률
--
EPS(TTM)
0.01
시가총액
$180.3M
AROAF란 무엇인가요?
Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. The company develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from the ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that serve as the building blocks for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM designed for soft tissue repair, reinforcement, and complex wounds.